Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.57 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 4/20 | 0.37 |
| ▸ | ASPH | Q12797 | 1/20 | 0.37 |
| ▸ | DAO | P14920 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | RXRA | P19793 | 1/20 | 0.35 |
| ▸ | RXRB | P28702 | 1/20 | 0.35 |
| ▸ | RXRG | P48443 | 1/20 | 0.35 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.35 |
| ▸ | GLRA3 | O75311 | 1/20 | 0.34 |
| ▸ | GLRB | P48167 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2514314 | 0.86 | HCAR2 (0.55) | HCAR2KDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL25373854 | 0.85 | HCAR2 (0.53) | HCAR2KDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL13956211 | 0.85 | HCAR2 (0.53) | HCAR2KDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL16814173 | 0.84 | ALDH1A1 (0.44) | HCAR2SLC6A3KDM4EALDH1A1HPGD | |
| SCHEMBL12868672 | 0.83 | HPGD (0.41) | HCAR2KDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL18183949 | 0.82 | BTK (0.39) | HCAR2SLC6A3KDM4EALDH1A1HPGD | |
| SCHEMBL17936109 | 0.82 | ALDH1A1 (0.38) | HCAR2SLC6A3KDM4EALDH1A1HPGD | |
| SCHEMBL26910746 | 0.80 | HCAR2 (0.49) | HCAR2KDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL9644194 | 0.80 | HCAR2 (0.52) | HCAR2KDM4EALDH1A1ASPHDAO | |
| SCHEMBL3989938 | 0.80 | HCAR2 (0.52) | HCAR2KDM4EALDH1A1HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4737449-A1 | P53-Y220C SELECTIVE SMALL-MOLECULAR REACTIVATOR COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Changchun Genescience Pharmaceutical Co., Ltd. (CN) | 2026-05-06 | — | — | EP | disclosed |
| CN-115304606-B | Degradation agent for simultaneously targeting BTK and GSPT proteins | 清华大学 | 2024-04-19 | — | — | CN | disclosed |
| US-20240043436-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2024-02-08 | — | — | US | disclosed |
| US-11807644-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| CN-116710430-A | Methods and compounds for restoring mutant p53 function | 皮姆维制药公司 | 2023-09-05 | — | — | CN | disclosed |
| EP-3444251-B1 | BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY | BIOGEN MA INC (US) | 2023-06-07 | — | — | EP | disclosed |
| EP-3444251-B1 | BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY | BIOGEN MA INC (US) | 2023-06-07 | — | — | EP | disclosed |
| EP-4149459-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | PMV Pharmaceuticals, Inc. (US) | 2023-03-22 | — | — | EP | disclosed |
| US-20230065745-A1 | PIPERIDINE-2,6-DIONE DERIVATIVES WHICH BIND TO CEREBLON, AND METHODS OF USE THEREOF | CAPTOR THERAPEUTICS S.A. (PL) | 2023-03-02 | — | — | US | disclosed |
| US-11572356-B2 | Biaryl inhibitors of Bruton's tyrosine kinase | BIOGEN MA INC. (US) | 2023-02-07 | — | — | US | disclosed |
| US-20100267669-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-10-21 | — | — | US | disclosed |
| US-7790770-B2 | Heterocyclic CETP inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-09-07 | — | — | US | disclosed |
| EP-2063897-A2 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Deciphera Pharmaceuticals, LLC. (US) | 2009-06-03 | — | — | EP | disclosed |
| US-20090048248-A1 | Octahydropyrano[3,4-C]Pyrrole Tachykinin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2009-02-19 | — | — | US | disclosed |
| US-20080114006-A1 | Kinase inhibitors useful for the treatment of proliferative diseases | DECIPHERA PARMACEUTICALS, LLC (US) | 2008-05-15 | — | — | US | disclosed |
| WO-2008034008-A2 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC. (US) | 2008-03-20 | — | — | WO | disclosed |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-12 | — | — | US | disclosed |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| US-5136042-A | PROCESS FOR THE PREPARATION OF THIAZOLECARBOXYLIC ACID CHLORIDES | MITSUI TOATSU CHEMICALS, INC. (JP) | 1992-08-04 | — | — | US | disclosed |
| EP-0377750-A1 | PROCESS FOR PREPARING THIAZOLECARBOXYLIC ACID CHLORIDES | MITSUI CHEMICALS, INC. (JP) | 1990-07-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11572356-B2 | Biaryl inhibitors of Bruton's tyrosine kinase | ABL1, BTK, LYN | HCAR2 4117/4885SLC6A3 4054/4885KDM4E 1273/4885 |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | HCAR2 979/4885SLC6A3 4839/4885KDM4E 1618/4885 |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | HCAR2 979/4885SLC6A3 4839/4885KDM4E 1618/4885 |
| US-11807644-B2 | Methods and compounds for restoring mutant p53 function | TP53, TP53BP1, HRAS | HCAR2 4088/4885SLC6A3 4192/4885KDM4E 3311/4885 |
| US-20240043436-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, HRAS | HCAR2 4088/4885SLC6A3 4192/4885KDM4E 3311/4885 |
| US-20100267669-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | HCAR2 979/4885SLC6A3 4839/4885KDM4E 1618/4885 |
| US-20090048248-A1 | Octahydropyrano[3,4-C]Pyrrole Tachykinin Receptor Antagonists | TACR1, TACR2, NPSR1 | HCAR2 348/4885SLC6A3 248/4885KDM4E 1864/4885 |
| US-20230065745-A1 | PIPERIDINE-2,6-DIONE DERIVATIVES WHICH BIND TO CEREBLON, AND METHODS OF USE THEREOF | CRBN, CDR2, FABP7 | HCAR2 736/4885SLC6A3 1699/4885KDM4E 2325/4885 |
| US-20080114006-A1 | Kinase inhibitors useful for the treatment of proliferative diseases | BRAF, PRKDC, RAF1 | HCAR2 3192/4885SLC6A3 2724/4885KDM4E 2009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.